cyc 202 has been researched along with Acute Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Ji, XL; Tian, F; Tian, LJ; Wang, B; Xu, LH | 1 |
| Boussiotis, V; Kim, Js; Li, L; Pihan, G; Wang, H | 1 |
3 other study(ies) available for cyc 202 and Acute Disease
| Article | Year |
|---|---|
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
The neuroprotective mechanism of puerarin in the treatment of acute spinal ischemia-reperfusion injury is linked to cyclin-dependent kinase 5.
Topics: Acute Disease; Animals; Apoptosis; Cyclin-Dependent Kinase 5; Enzyme Activation; Infarction; Isoflavones; Male; Neuroprotective Agents; Phosphotransferases; Purines; Rats, Sprague-Dawley; Reperfusion Injury; Roscovitine; Spinal Cord; Spinal Cord Ischemia | 2015 |
The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD.
Topics: Acute Disease; Animals; Cell Cycle; Cell Line; Cyclin-Dependent Kinase 2; Female; Graft vs Host Disease; Mice; Mice, Inbred C57BL; Models, Animal; NF-kappa B; Protein Kinase Inhibitors; Purines; Roscovitine; Signal Transduction; Smad3 Protein; Survival Rate; T-Lymphocytes; Transplantation, Heterologous; Tumor Necrosis Factor-alpha | 2009 |